Viewing Study NCT02821000


Ignite Creation Date: 2025-12-26 @ 12:16 PM
Ignite Modification Date: 2026-03-04 @ 8:14 PM
Study NCT ID: NCT02821000
Status: COMPLETED
Last Update Posted: 2024-05-30
First Post: 2016-06-29
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PD1 View
None PD-1 View
None PDL1 View
None PD-L1 View